Cite
MLA Citation
Philip Carlucci et al.. “1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms.” Lupus science & medicine, vol. 9, n.d., pp. A102–A103. http://access.bl.uk/ark:/81055/vdc_100172521750.0x00001e